A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
for Advanced Renal Cell Carcinoma (RCC)
Drug: Cabozantinib
13 locations incl. New Haven
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07293351·Phase 1, Phase 2·Recruiting